Tivic Health Systems Inc (TIVC) - Total Liabilities
Based on the latest financial reports, Tivic Health Systems Inc (TIVC) has total liabilities worth $27.15 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Tivic Health Systems Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Tivic Health Systems Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Tivic Health Systems Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Tivic Health Systems Inc balance sheet assets.
Tivic Health Systems Inc Competitors by Total Liabilities
The table below lists competitors of Tivic Health Systems Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hedera Group publ AB
ST:HEGR
|
Sweden | Skr122.20 Million |
|
NO GRAVITY GAMES ZY -10
F:8YX
|
Germany | €776.14K |
|
ModuLink Inc.
NASDAQ:MDLK
|
USA | $775.74K |
|
PowerCompute, Inc.
NASDAQ:PWCM
|
USA | $21.56 Million |
|
Atomic Minerals Corp
V:ATOM
|
Canada | CA$1.15 Million |
|
Yangaroo Inc
V:YOO
|
Canada | CA$3.79 Million |
|
RBR Group Ltd
AU:RBR
|
Australia | AU$2.08 Million |
|
Universe Pharmaceuticals Inc
NASDAQ:UPC
|
USA | $13.17 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Tivic Health Systems Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Tivic Health Systems Inc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tivic Health Systems Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tivic Health Systems Inc (2019–2025)
The table below shows the annual total liabilities of Tivic Health Systems Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $14.81 Million | +5344.85% |
| 2024-12-31 | $272.00K | -82.75% |
| 2023-12-31 | $1.58 Million | -33.96% |
| 2022-12-31 | $2.39 Million | +35.37% |
| 2021-12-31 | $1.76 Million | -34.86% |
| 2020-12-31 | $2.71 Million | +314.70% |
| 2019-12-31 | $653.00K | -- |
About Tivic Health Systems Inc
Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offe… Read more